Search: onr:"swepub:oai:lup.lub.lu.se:561cc7ce-1509-451a-925c-967b5ec7b7ba" >
The Effect of Evero...
The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial
-
Arora, S. (author)
-
Andreassen, A. K. (author)
-
Andersson, B. (author)
-
show more...
-
Gustafsson, F. (author)
-
Eiskjaer, H. (author)
-
Botker, H. E. (author)
-
- Rådegran, Göran (author)
- Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Gude, E. (author)
-
Ioanes, D. (author)
-
Solbu, D. (author)
-
Sigurdardottir, V. (author)
-
Dellgren, G. (author)
-
Erikstad, I. (author)
-
Solberg, O. G. (author)
-
Ueland, T. (author)
-
Aukrust, P. (author)
-
Gullestad, L. (author)
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2015
- 2015
- English.
-
In: American Journal of Transplantation. - : Elsevier BV. - 1600-6135. ; 15:7, s. 1967-1975
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Early initiation of everolimus with calcineurin inhibitor therapy has been shown to reduce the progression of cardiac allograft vasculopathy (CAV) in de novo heart transplant recipients. The effect of de novo everolimus therapy and early total elimination of calcineurin inhibitor therapy has, however, not been investigated and is relevant given the morbidity and lack of efficacy of current protocols in preventing CAV. This 12-month multicenter Scandinavian trial randomized 115 de novo heart transplant recipients to everolimus with complete calcineurin inhibitor elimination 7-11 weeks after HTx or standard cyclosporine immunosuppression. Ninety-five (83%) patients had matched intravascular ultrasound examinations at baseline and 12 months. Mean (SD) recipient age was 49.9 +/- 13.1 years. The everolimus group (n=47) demonstrated significantly reduced CAV progression as compared to the calcineurin inhibitor group (n=48) (Maximal Intimal Thickness 0.03 +/- 0.06 and 0.08 +/- 0.12mm, Percent Atheroma Volume 1.3 +/- 2.3 and 4.2 +/- 5.0%, Total Atheroma Volume 1.1 +/- 19.2mm(3) and 13.8 +/- 28.0mm(3) [all p-values0.01]). Everolimus patients also had a significantly greater decline in levels of soluble tumor necrosis factor receptor-1 as compared to the calcineurin inhibitor group (p=0.02). These preliminary results suggest that an everolimus-based CNI-free can potentially be considered in suitable de novo HTx recipients.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Arora, S.
-
Andreassen, A. K ...
-
Andersson, B.
-
Gustafsson, F.
-
Eiskjaer, H.
-
Botker, H. E.
-
show more...
-
Rådegran, Göran
-
Gude, E.
-
Ioanes, D.
-
Solbu, D.
-
Sigurdardottir, ...
-
Dellgren, G.
-
Erikstad, I.
-
Solberg, O. G.
-
Ueland, T.
-
Aukrust, P.
-
Gullestad, L.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
American Journal ...
- By the university
-
Lund University